Source
Pharmaceutical
The partnership will see Viz.ai develop an AI Care Pathway for cardiac amyloidosis.
Viz.ai has entered a collaboration with Alnylam to advance earlier identification and streamline diagnosis for cardiac amyloidosis, an underdiagnosed cause of heart failure.
Cardiac amyloidosis is a progressive condition where misfolded proteins accumulate in the heart muscle, often leading to heart failure.
There are two main types of cardiac amyloidosis: wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), and light chain amyloidosis (AL).
News Url